Browse Negotiations Image Banner

Banner Text Velit velaliquam, ultricies eros dolore magna in in doming ullamco sint. Sint doming dignissim in quis pariatur consequat urna eu providerent. Sint dolore ea urna velit doming ea pulvinar.

General Callout

Nunc dolor esse suscipit eros eros ullamco dolor. Duis velaliquam sunt urna, tempuribud doming quis, laboris ultricies ultricies urna laboris. Nostrud pulvinar nostrud elit sunt ex exercitation magna tempuribud laboris ea ex nunc sed exercitation ea laboris dignissim.

Accordion

Quis harmud ea commodo voluptate dolor urna providerent tempor amet dignissim velit consectetur harmud sint doming, urna magna velit sed commodo urna sint sunt nunc. Nunc consectetur laboris harmud dolore exercitation sed magna laboris nulla velit velaliquam ultricies. Dignissim adipiscing, sed duis ultricies sint voluptate providerent nunc nisi.

Heading 1

Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.

Heading 2

Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.

Related content

Dolor commodo suscipit adipiscing suscipit, elit dolore velit. Amet tempuribud velit pariatur ullamco exercitation esse dolore sint velaliquam adipiscing eu pulvinar doming sunt, dignissim velit voluptate ex suscipit sunt ex, duis dignissim nunc tempuribud laboris commodo velit ut. Velit in harmud quis voluptate esse nulla.

Shop Now!

Laboris quis consectetur sed eros velit tempuribud suscipit magna ea consequat laboris. Elit adipiscing quis sunt duis magna nulla velit amet elit ex providerent consectetur tempuribud amet ex commodo urna, magna adipiscing elit sed duis nisi pulvinar, doming pariatur velaliquam quis providerent fugiat ea aliquip sit ut nisi sunt pulvinar eu velit.

grey rec centre

Call to action

Esse suscipit in eros ea sed voluptate dolore, harmud nisi, dolore ultricies fugiat amet doming ut sint ut adipiscing. Sit velit velaliquam ex nunc ut voluptate

Primary Button Secondary Button

Search by drug, manufacturer, or indication

Displaying 851 - 860 of 1165

Alecensaro (alectinib)

Status:

Concluded with an LOI

Manufacturer:

Hoffmann-La Roche Ltd.

Indication:

Non-small cell lung cancer (NSCLC), locally advanced or metastatic

Last updated December 11, 2018

Gazyva (obinutuzumab)

Status:

Negotiations were not pursued

Manufacturer:

Hoffmann-La Roche Ltd.

Indication:

Follicular lymphoma, Relapsed or refractory

Last updated December 7, 2018

Actemra (tocilizumab)

Status:

Concluded with an LOI

Manufacturer:

Hoffmann-La Roche Ltd.

Indication:

Giant Cell Arteritis

Last updated December 6, 2018

Izba (travoprost)

Status:

Concluded with an LOI

Manufacturer:

Novartis Pharmaceuticals Canada Inc.

Indication:

Open-angle Glaucoma

Last updated December 6, 2018

Ozanex (ozenoxacin)

Status:

Negotiations were not pursued

Manufacturer:

Ferrer Internacional

Indication:

Impetigo

Last updated November 30, 2018

Ozurdex (dexamethasone)

Status:

Negotiations were not pursued

Manufacturer:

Allergan Inc.

Indication:

Diabetic Macular Edema

Last updated November 29, 2018

Nucynta (tapentadol hydrochloride)

Status:

Negotiations were not pursued

Manufacturer:

Paladin Labs Inc.

Indication:

Pain, severe

Last updated November 29, 2018

Tecentriq (atezolizumab)

Status:

Concluded with an LOI

Manufacturer:

Hoffmann-La Roche Ltd.

Indication:

Non-small Cell Lung Cancer

Last updated November 29, 2018

Copaxone (glatiramer acetate)

Status:

Concluded without agreement

Manufacturer:

Teva Canada Ltd.

Indication:

Clinically Isolated Syndrome

Last updated November 29, 2018

Vimizim (elosulfase alfa)

Status:

Concluded with an LOI

Manufacturer:

BioMarin Pharmaceutical Inc.

Indication:

Mucopolysaccharidosis IVA (Morquio A syndrome)

Last updated November 29, 2018